KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Current Liabilities (2016 - 2025)

NovoCure's Total Current Liabilities history spans 12 years, with the latest figure at $223.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 70.49% year-over-year to $223.2 million; the TTM value through Dec 2025 reached $223.2 million, down 70.49%, while the annual FY2025 figure was $223.2 million, 70.49% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $223.2 million at NovoCure, down from $776.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $776.0 million in Q3 2025 and bottomed at $110.5 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $158.0 million (2022), against an average of $300.3 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 367.67% in 2024 before it tumbled 70.49% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $142.6 million in 2021, then rose by 11.34% to $158.8 million in 2022, then increased by 12.81% to $179.1 million in 2023, then surged by 322.3% to $756.4 million in 2024, then crashed by 70.49% to $223.2 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Total Current Liabilities are $223.2 million (Q4 2025), $776.0 million (Q3 2025), and $749.6 million (Q2 2025).